🔵 BIG PICTURE LOGIC (EXAM GOLD)

Thrombosis prevention happens at 2 levels:

1️⃣ Platelet phase → arterial clots

→ Aspirin

2️⃣ Coagulation cascade → venous clots

→ Heparin / Warfarin

👉 Artery = platelet problem

👉 Vein = coagulation factor problem

🟩 ASPIRIN (ANTIPLATELET)

1️⃣ CLASSIFICATION

• NSAID
• Antiplatelet (LOW DOSE)

👉 High dose = analgesic/anti-inflammatory

👉 Low dose = antiplatelet

2️⃣ MECHANISM — WHY IT’S UNIQUE

🔬 Molecular action

• Irreversibly inhibits COX-1 in platelets
• ↓ Thromboxane A₂ (TXA₂)
• ↓ Platelet aggregation
• ↓ Vasoconstriction

🧠 KEY LOGIC

• Platelets cannot synthesize new COX (no nucleus)
• So effect lasts entire platelet lifespan (7–10 days)

📌 One tablet → 1 week effect

3️⃣ PHARMACOKINETICS (WHY EFFECT LASTS LONGER THAN HALF-LIFE)

• Oral absorption: good
• First-pass metabolism → liver
• Plasma half-life: 2–4 hours
• Functional effect: 7 days

👉 EXAM TRAP:

Half-life ≠ duration of antiplatelet action

4️⃣ CLINICAL USES — LOGIC BASED

🫀 CARDIOVASCULAR

• ACS (acute MI)
• Secondary prevention of MI
• Stroke / TIA prevention
• Peripheral arterial disease

🤰 OBGYN (VERY HIGH-YIELD)

• Preeclampsia prevention
• Low-dose (75–150 mg)
• Start from 12 weeks
• Especially:
• Previous PET
• Chronic HTN
• Diabetes
• Autoimmune disease
• Multiple pregnancy

👉 WHY?

Improves placental perfusion by ↓ platelet microthrombi

5️⃣ ADVERSE EFFECTS — MECHANISM LINKED

⚠️ Aspirin-exacerbated respiratory disease (AERD)

6️⃣ CONTRAINDICATIONS — THINK WHY

❌ Active peptic ulcer → bleeding risk

❌ Aspirin-sensitive asthma → bronchospasm

❌ Bleeding disorders → platelet dysfunction

❌ Children with viral illness → Reye syndrome

7️⃣ EXAM PEARLS

• Irreversible
• Platelet effect lasts 7 days
• Stop aspirin 7 days before surgery
• Arterial thrombosis drug

Elaborative clinical scenario that connects EVERYTHING about low-dose aspirin (antiplatelet) — without missing any point

Scene 1 — The patient + the OBGYN link (why low dose)

A 32-year-old woman (G2P1) comes to antenatal clinic at 12 weeks.

She has:

• Previous preeclampsia (PET) in last pregnancy
• Chronic hypertension (on treatment)
• Type 1 diabetes
• This pregnancy is twins (multiple pregnancy)

You immediately recognize she is high risk for preeclampsia.

✅ You start low-dose aspirin 75–150 mg daily from 12 weeks.

Why (logic):

• In high-risk pregnancies, placental vessels can develop platelet microthrombi and poor remodeling → placental perfusion drops.
• Low-dose aspirin decreases platelet aggregation → fewer microthrombi → better placental perfusion → reduces risk of PET.

This single decision already connects:

• OBGYN use (preeclampsia prevention)
• Dose range (75–150 mg)
• Timing (start from 12 weeks)
• Who to give (previous PET, chronic HTN, diabetes, autoimmune disease, multiple pregnancy)
• The mechanism-based “why” (microthrombi → perfusion)

Scene 2 — Classification + dose-dependent effect

While prescribing, you counsel her:

• “Aspirin is an NSAID, but at low dose it acts mainly as an antiplatelet.”
• “If we use high doses, it behaves more like a usual NSAID (analgesic/anti-inflammatory), which is not what we want here.”

✅ This connects:

• Classification: NSAID
• Low dose = antiplatelet
• High dose = analgesic/anti-inflammatory

Scene 3 — Why aspirin is UNIQUE (irreversible COX-1 block)

You explain the exact antiplatelet mechanism:

• Aspirin irreversibly inhibits COX-1 in platelets
• That leads to ↓ thromboxane A₂ (TXA₂)
• So ↓ platelet aggregation
• And ↓ vasoconstriction (TXA₂ normally promotes vasoconstriction too)

Then you add the exam-critical logic:

• Platelets have no nucleus
• So they cannot synthesize new COX enzyme
• Therefore the effect lasts the whole platelet lifespan: 7–10 days

📌 You tell her:

“Even one dose affects platelets for about a week.”

✅ This connects:

• COX-1
• TXA₂
• ↓ aggregation + ↓ vasoconstriction
• Irreversible
• No nucleus → cannot regenerate COX
• Duration 7–10 days (“one tablet → 1 week effect”)

Scene 4 — Pharmacokinetics trap (half-life vs duration)

A few days later, she asks:

“Doctor, if aspirin stays only a few hours in blood, how can it work for a week?”

You clarify:

• Aspirin is well absorbed orally
• It undergoes first-pass metabolism in the liver
• Its plasma half-life is short (2–4 hours)
• But the functional antiplatelet effect lasts ~7 days because it permanently disables platelet COX-1, and platelets can’t replace it.

✅ You highlight the exam trap:

“Half-life is NOT the same as duration of antiplatelet effect.”

Scene 5 — Cardiovascular crossover (arterial thrombosis logic)

At 28 weeks, her father (55) comes with her to clinic and says he recently had chest pain and was told he had an ACS (acute MI).

You explain why aspirin is a core drug there:

• Aspirin is an arterial thrombosis drug (platelet-rich clots)
• Used in:
• ACS / acute MI
• Secondary prevention of MI
• Stroke / TIA prevention
• Peripheral arterial disease

✅ This connects all CV uses + the “arterial thrombosis” exam pearl.

Scene 6 — Adverse effects appear (mechanism-linked)

At 30 weeks, the pregnant patient returns with:

• Epigastric burning pain
• She says she had black stools once (possible melena)

You immediately think aspirin GI effects:

Mechanism link:

• COX-1 inhibition → ↓ protective prostaglandins in gastric mucosa → gastritis
• Plus platelet inhibition → GI bleeding risk increases
• So aspirin can cause both:
• Gastritis
• GI bleeding

✅ This connects adverse effects table:

• Gastritis = ↓ prostaglandins (COX-1 block)
• GI bleeding = platelet inhibition + mucosal injury

You reassess and ask about ulcer history because:

❌ Active peptic ulcer disease is a contraindication (bleeding risk).

Scene 7 — Salicylate toxicity clue (tinnitus)

She also casually says:

“Sometimes my ears are ringing.”

You recognize:

• Tinnitus is a classic sign of salicylate toxicity

✅ This links “tinnitus → salicylate toxicity.”

Scene 8 — Bronchospasm + leukotriene shunt (AERD)

Then she mentions:

“After taking it, I once felt tightness in my chest and wheeze.”

You immediately check asthma history, because aspirin can cause bronchospasm through the classic pathway:

• Aspirin blocks COX → ↓ prostaglandins (especially PGE₂, which normally has bronchodilator/airway-protective effects)
• Arachidonic acid pathway gets pushed toward 5-lipoxygenase
• ↑ Leukotrienes LTC₄, LTD₄, LTE₄
• → bronchoconstriction + mucus + airway edema
• This is the basis of aspirin-exacerbated respiratory disease (AERD)

✅ This connects:

• Bronchospasm
• Leukotriene shunt
• PGE₂ drop
• 5-lipoxygenase
• LTC₄/LTD₄/LTE₄
• AERD

So:

❌ Aspirin-sensitive asthma is a contraindication.

Scene 9 — Contraindications recap (all “think why”)

You do a full safety screen and explicitly connect each contraindication to logic:

• ❌ Active peptic ulcer → bleeding risk (mucosal injury + platelet inhibition)
• ❌ Aspirin-sensitive asthma/AERD → bronchospasm via leukotrienes
• ❌ Bleeding disorders → worsens bleeding due to platelet dysfunction
• ❌ Children with viral illness → risk of Reye syndrome

(You also tell her not to give aspirin to kids at home for viral fever.)

✅ This completes the entire contraindication list.

Scene 10 — Surgery/Procedure planning (stop 7 days)

At 37 weeks, the obstetric team plans an elective C-section.

The anesthetist asks:

“Is she on aspirin?”

You reply:

• “Yes — low dose.”
• “We should stop aspirin 7 days before surgery because platelet function won’t recover until new platelets are produced.”

✅ This connects the exam pearls:

• Irreversible
• Platelet effect lasts ~7 days
• Stop 7 days before surgery

✅ Everything connected (quick checklist)

This single storyline included, in-context:

• NSAID class + low dose antiplatelet vs high dose analgesic/anti-inflammatory
• Irreversible COX-1 inhibition → ↓ TXA₂ → ↓ aggregation + ↓ vasoconstriction
• Platelets no nucleus → can’t resynthesize COX → 7–10 day effect
• PK: good absorption, first-pass liver, half-life 2–4h but effect 7d (trap)
• Uses: ACS/MI, secondary prevention, stroke/TIA, PAD
• OBGYN: PET prevention 75–150 mg from 12 weeks + high-risk groups + placental microthrombi logic
• Adverse: gastritis, GI bleed, tinnitus (salicylate toxicity), bronchospasm (leukotriene shunt) + AERD
• Contraindications: active PUD, aspirin asthma, bleeding disorders, children viral illness (Reye)
• Exam pearl: stop 7 days before surgery

🟦 HEPARIN (ANTICOAGULANT — IMMEDIATE)

1️⃣ TYPES

🔹 Unfractionated Heparin (UFH)

🔹 Low Molecular Weight Heparin (LMWH)

• Enoxaparin
• Dalteparin

2️⃣ MECHANISM — CORE LOGIC

• Binds Antithrombin III
• Accelerates inactivation of:
• Factor Xa
• Thrombin (IIa)

📌 UFH → Xa + IIa

📌 LMWH → mostly Xa

3️⃣ WHY UFH & LMWH BEHAVE DIFFERENTLY

4️⃣ PHARMACOKINETICS

UFH

• IV / SC
• Immediate action
• Short half-life
• Variable bioavailability
• Needs aPTT monitoring

LMWH

• SC only
• Predictable dose-response
• Renal excretion
• No routine monitoring

5️⃣ CLINICAL USES — LOGIC BASED

🦵 VENOUS THROMBOSIS

• DVT
• Pulmonary embolism

🫀 CARDIAC

• ACS
• During PCI

🤰 PREGNANCY (VERY IMPORTANT)

• Drug of choice
• Does NOT cross placenta
• No teratogenicity

🔄 BRIDGING THERAPY

• Used when stopping warfarin before surgery

6️⃣ ADVERSE EFFECTS

🔴 BLEEDING

• Most common

🔴 HIT (Heparin-Induced Thrombocytopenia)

• Immune-mediated
• Antibodies against heparin-PF4 complex
• Causes paradoxical thrombosis

⚠️ Platelets ↓ but clotting ↑

🔴 OSTEOPOROSIS

• Long-term UFH

7️⃣ ANTIDOTE

• Protamine sulfate
• Positively charged
• Binds heparin

📌 Fully reverses UFH

📌 Partially reverses LMWH

8️⃣ CONTRAINDICATIONS

❌ Previous HIT

❌ Active bleeding

❌ Severe thrombocytopenia

9️⃣ EXAM PEARLS

• Immediate onset
• Safe in pregnancy
• Monitor UFH with aPTT
• HIT = thrombosis + thrombocytopenia

Clinical scenario (ties every single point together)

A 29-year-old woman, 10 weeks pregnant, comes to the ED with a swollen, painful left calf for 2 days. She had a long bus ride from Jaffna to Colombo. She has no fever. On exam: calf tenderness and mild pitting edema. Her vitals are stable.

A bedside Doppler suggests proximal DVT.

1) Why “heparin” is chosen immediately (and why it’s pregnancy-safe)

Because she is pregnant, you avoid warfarin and choose heparin as drug of choice:

• Heparin does NOT cross the placenta → no teratogenicity
• So in pregnancy, UFH or LMWH are used for acute treatment and prevention.

You explain to her:

“We need an anticoagulant that works right away and is safe for the baby.”

That’s why you start heparin immediately.

2) Mechanism in the story (core logic in action)

You tell the intern:

• Heparin binds Antithrombin III
• This accelerates inactivation of:
• Factor Xa
• Thrombin (Factor IIa)

And you highlight the exam distinction:

• UFH → inhibits Xa + IIa (thrombin)
• LMWH → mostly Xa(Factor Xa converts prothrombin (Factor II) → thrombin (Factor IIa))

This is the “why clot stops growing” mechanism in her DVT.

3) Choosing UFH vs LMWH using the table logic

Option A: LMWH pathway (most common in stable pregnancy DVT)

She is stable, no shock, no massive PE signs. So you pick LMWH (e.g., enoxaparin) because:

• Predictable dose-response
• No routine monitoring
• Longer half-life (4–6 h) → convenient dosing
• Less day-to-day variability than UFH

But you first check renal function because:

• LMWH is renally cleared (renal excretion)

So you order creatinine/eGFR before final dosing.

Option B: When UFH becomes the better choice

Two hours later, she develops sudden pleuritic chest pain + mild breathlessness. You suspect pulmonary embolism.

Now you consider UFH if you need maximum control because:

• Immediate action (especially IV)
• Short half-life (1–2 h) → easy to stop/adjust rapidly
• Reversal is complete with protamine
• Less dependence on renal clearance

So you switch to IV UFH if PE is significant or if procedures may be needed soon.

4) Pharmacokinetics shown through decisions

UFH in real-time

You start IV UFH (because you want tight control):

• IV / SC possible
• Immediate action
• Short half-life
• Variable bioavailability → dose response can be unpredictable
• Therefore you must monitor with aPTT

So you order:

• Baseline platelet count
• Baseline aPTT
• Then aPTT monitoring to keep in therapeutic range

LMWH in real-time

If she stays stable and renal function is normal, you use SC LMWH:

• SC only
• Predictable dose-response
• Renal excretion
• No routine monitoring

(You’d only consider monitoring in special situations, but your note says “not routine,” so the story sticks to that.)

5) Clinical uses appear in one patient’s journey

This same case can touch multiple “heparin uses”:

✅ Venous thrombosis

• She has DVT, and possibly PE → classic heparin indication.

✅ Pregnancy

• She’s pregnant → heparin is the drug of choice.

✅ Bridging therapy (later in the timeline)

Fast-forward: after delivery, she is found to have a thrombophilia and is planned for long-term anticoagulation with warfarin.

You explain bridging:

• Warfarin takes time to become fully effective.
• So you overlap heparin until warfarin is therapeutic.

Also, months later she needs a minor surgery. You stop warfarin pre-op and use heparin bridging again because it’s short acting and controllable.

✅ Cardiac use (teaching moment)

During ward teaching, the consultant says:

• Same drugs are used in ACS and during PCI because immediate anticoagulation is needed.

(So the intern sees that heparin isn’t only for DVT/PE.)

6) Adverse effects appear as complications you watch for

A) Bleeding (most common)

On day 2 of UFH infusion, she reports gum bleeding when brushing. You check:

• Any drop in Hb?
• Any overt bleeding?

You adjust the infusion based on aPTT because UFH levels can swing.

B) HIT — the “paradox” complication (thrombosis + low platelets)

On day 6, her platelet count falls significantly compared with baseline, and she suddenly gets new pain in the other leg.

You connect the classic mechanism:

• HIT is immune-mediated
• Antibodies against heparin–PF4 complex
• Causes paradoxical thrombosis even though platelets are low:

Platelets ↓ but clotting ↑

This instantly triggers action:

• Stop all heparin (UFH or LMWH)
• Mark her chart: “Previous HIT” permanently

C) Osteoporosis (long-term UFH)

The consultant warns:

• With long-term UFH, there’s risk of osteoporosis
• Another reason many clinicians prefer LMWH for longer courses when appropriate.

7) Antidote used in a real emergency

That night she develops heavy bleeding from a cannula site and her aPTT is very prolonged.

You give protamine sulfate:

• Positively charged
• Binds heparin

And you emphasize the exam line in the moment:

• Fully reverses UFH
• Partially reverses LMWH

So if she had been on LMWH, protamine helps but may not completely reverse.

8) Contraindications applied to the same patient

After the HIT episode, you summarize contraindications:

• Previous HIT → absolute “never again heparin”
• Active bleeding → don’t give heparin
• Severe thrombocytopenia → avoid

This is why her HIT history becomes critical for future admissions.

9) Exam pearls, embedded naturally in the case

By the end of the ward round, the intern can say:

• Heparin has immediate onset
• Safe in pregnancy (does not cross placenta)
• UFH monitoring = aPTT
• HIT = thrombocytopenia + thrombosis
• Protamine reverses UFH fully, LMWH partially
• UFH: short half-life, variable response
• LMWH: predictable response, renal excretion, longer half-life

That’s the entire table + mechanisms + uses + complications, all living inside one coherent clinical storyline.

🟥 WARFARIN (ORAL LONG-TERM ANTICOAGULANT)

1️⃣ CLASS

• Vitamin K antagonist
• Oral anticoagulant

2️⃣ MECHANISM — STEPWISE LOGIC

• Inhibits vitamin K epoxide reductase
• ↓ γ-carboxylation of:
• Factors II, VII, IX, X
• Proteins C & S

📌 Protein C falls FIRST → transient hypercoagulable state

3️⃣ PHARMACOKINETICS

• Oral
• Highly protein-bound
• Hepatic metabolism (CYP450)
• Long half-life: 36–42 h
• Delayed onset (2–3 days)

👉 Needs bridging with heparin initially

4️⃣ MONITORING

• INR
• Target: 2–3
• Mechanical valve: 2.5–3.5

5️⃣ USES

• Mechanical heart valves
• Atrial fibrillation
• DVT / PE long-term
• Thrombophilia

6️⃣ ADVERSE EFFECTS

🔴 BLEEDING (MOST COMMON)

🔴 SKIN NECROSIS

• Due to early protein C depletion
• Occurs 3–5 days after start

🔴 TERATOGENICITY

• Fetal warfarin syndrome:
• Nasal hypoplasia
• Stippled epiphyses
• CNS defects

7️⃣ ANTIDOTES — STEPWISE

8️⃣ CONTRAINDICATIONS

❌ Pregnancy

❌ Active bleeding

❌ Liver disease

❌ Poor compliance

9️⃣ EXAM PEARLS

• Delayed onset
• Needs INR monitoring
• Many drug & food interactions
• NEVER in pregnancy

🩺 Integrated Clinical Scenario — Warfarin in One Story

A 62-year-old man with long-standing atrial fibrillation and a recent unprovoked DVT is admitted for initiation of long-term anticoagulation. He has normal renal function, mild fatty liver on ultrasound, and no active bleeding.

Day 0 – Decision to start therapy

Because he needs lifelong anticoagulation, the team decides to start warfarin (oral, long-term) rather than continuing injections.

However, the registrar explains:

“Warfarin has a delayed onset and causes early protein C depletion, so we must bridge with heparin.”

👉 He is started on LMWH + warfarin together.

Day 2–3 – Understanding the mechanism

• Warfarin inhibits vitamin K epoxide reductase
• This reduces activation of Factors II, VII, IX, X
• Protein C falls first → short period of hypercoagulability

📌 Why bridging matters:

Without heparin, he could paradoxically form clots or develop skin necrosis.

Day 4 – Monitoring

His INR is checked daily.

• Day 3 INR: 1.6
• Day 5 INR: 2.3

Once INR stays between 2–3 for >24 hours, LMWH is stopped.

Week 2 – Complication avoided

A colleague mentions another patient who developed painful black skin lesions on thighs on day 4 of warfarin.

👉 Diagnosis: Warfarin-induced skin necrosis

👉 Cause: Early protein C depletion

Our patient avoids this because:

• He was properly bridged
• Dose was titrated using INR

Follow-up clinic – Safety counseling

He is educated about:

• Regular INR monitoring
• Drug interactions (antibiotics, NSAIDs)
• Food interactions (vitamin K–rich leafy greens)
• Warning signs of bleeding

Red flag scenario (exam favorite)

A 28-year-old pregnant woman with a mechanical valve asks for warfarin.

❌ Absolute contraindication

Why?

• Warfarin crosses placenta
• Causes fetal warfarin syndrome:
• Nasal hypoplasia
• Stippled epiphyses
• CNS defects

👉 She must be switched to heparin, not warfarin.

Emergency twist

Six months later, the man presents with:

• Massive GI bleed
• INR = 6.5

Management:

• Stop warfarin
• Give PCC immediately
• If unavailable → FFP
• Add vitamin K

🧠 One-line examiner takeaway

Warfarin is a delayed-onset oral vitamin K antagonist requiring heparin bridging, INR monitoring, avoided in pregnancy, and reversed with vitamin K ± PCC in bleeding.

🔥 FINAL EXAM COMPARISON TABLE (LOCK THIS)

🧠 ONE-LINE MEMORY LOCK

Aspirin kills platelets

Heparin blocks clotting NOW

Warfarin blocks clotting LATER